ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0985

Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry

Daniel Solomon1, Fredrik Johansson2, Hongshu Guan3, Leah Santacroce4, Lin Guo5, Wendi Malley5 and Heather Litman5, 1Brigham and Women's Hospital, Newton, MA, 2Chalmers University of Technology, Goteborg, Sweden, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5CorEvitas, LLC, Waltham, MA

Meeting: ACR Convergence 2023

Keywords: Comorbidity, Epidemiology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0965–0992) Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Comorbid conditions are very common in rheumatoid arthritis (RA) and several prior studies have derived comorbidity clusters using machine learning (ML). Clustering using ML is straightforward, but clusters only have value if they better explain clinical outcomes. We applied various ML algorithms to compare the clusters of comorbidities derived and to assess the value of the clusters for predicting clinical disease activity (CDAI) and function.

Methods: A large US-based RA registry, CorEvitas, was used to identify patients for the analysis. We assessed the presence of 24 comorbidities, and ML was used to derive comorbidity clusters. K-mode, K-mean, regression-based, and hierarchical clustering was used. To assess the value of the clusters, we compared them in clinical outcome models predicting clinical disease activity index (CDAI) and health assessment questionnaire (HAQ). We used data from the first three years of the six-year study period to derive clusters and assess time-averaged values for CDAI and HAQ during the latter three years. Model fit was assessed via adjusted R2 and Root Mean Square Error for a series of models that included clusters from K-mode and each of the 24 comorbidities separately. K-mode was selected as it was representative of the ML-based clustering algorithms.

Results: 11,883 patients with RA were included who had longitudinal data over 6 years. At baseline, patients were on average 59 (SD 8) years of age, 77% were women, CDAI was 11.1 (SD 3.4, moderate disease activity), HAQ was 0.32 (SD 0.11), and disease duration was 10.9 (SD 4.3) years. During the six years of follow-up, the percentage of patients with various comorbidities increased (Table 1). Using five clusters produced by the K-mode ML algorithm, multivariable regression models with time-averaged CDAI as an outcome found that entering K-mode comorbidity clusters produced similarly strong models as models with each of the 24 separate comorbidities entered individually (Table 2). The same patterns were observed for HAQ (Table3). The other ML-based clustering algorithms produced very similar model results.

Conclusion: Clustering comorbidities using ML algorithms is not computationally complex but often results in clusters that are difficult to interpret from a clinical standpoint. While ML clustering is very useful for biologic modeling, using clusters to predict outcomes produces models with similar fit as those with individual comorbidities. Other use cases for comorbidity clusters might help demonstrate underlying biology.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: D. Solomon: CorEvitas, 5, Janssen, 5, Moderna, 5, Novartis, 5; F. Johansson: None; H. Guan: None; L. Santacroce: None; L. Guo: CorEvitas, LLC, 3; W. Malley: None; H. Litman: CorEvitas, 3, 12, Shareholder.

To cite this abstract in AMA style:

Solomon D, Johansson F, Guan H, Santacroce L, Guo L, Malley W, Litman H. Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/assessing-the-value-of-comorbidity-clusters-in-predicting-clinical-outcomes-in-rheumatoid-arthritis-a-machine-learning-approach-using-a-very-large-us-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-the-value-of-comorbidity-clusters-in-predicting-clinical-outcomes-in-rheumatoid-arthritis-a-machine-learning-approach-using-a-very-large-us-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology